Ben Okonkwo: Can I make a prediction before you do?
Marcus Vale: This should be good.
Ben Okonkwo: I predict you already have a thesis on Intellia's lonvo-z data and I'm going to spend the next hour asking what experiment would have to fail for you to update it.
Marcus Vale: Honestly — yeah, fair. But read me the number first.
Ben Okonkwo: 87% reduction in HAE attacks. Single IV dose. Which is — okay, that got me too, I'm not going to pretend it didn't. But the trial tracked patients for 24 weeks, and Intellia is implying a lifetime benefit from that.
Marcus Vale: So the question is whether 24 weeks of clean data on a gene edit is enough to call it permanent — and frankly, the market is already deciding yes.
Marcus Vale: Eighty-seven percent reduction in HAE attacks. Single IV dose. Sixty-two percent of patients attack-free and off prophylaxis at six months. HAELO hit every number, and the data landed in the New England Journal of Medicine. That is not a press release — that's a peer-reviewed Phase 3 result.
Ben Okonkwo: All true. But tell me the window. Because I think that number does a lot of work.
Marcus Vale: Weeks five to twenty-eight. Yeah.
Ben Okonkwo: That's twenty-four weeks. And lonvo-z permanently edits KLKB1 in the liver. The company is calling it lifelong protection. Those two things are not the same claim.
Marcus Vale: Here's the deal — the mechanism supports the extrapolation. You knock out the gene encoding kallikrein B1, you cut off the pathway that produces bradykinin. Hepatocytes don't regenerate KLKB1 expression after an in vivo CRISPR edit. The edit is permanent by design.
Ben Okonkwo: The mechanism is plausible. I'm not arguing the mechanism. What I'm asking is — what happens to sustained kallikrein suppression in year three, year five? Kallikrein touches immune signaling, coagulation. We don't have that data. The safety readout from HAELO is mild-to-moderate TEAEs over six months. That's a different question than rare adverse events in ten thousand patients over a decade.
Marcus Vale: Okay, but — regulators have approved permanent genetic edits before. Zolgensma went through on durability extrapolation from follow-up data that wasn't multi-decade either.
Ben Okonkwo: Zolgensma targets pediatric SMA. You're dosing infants with a natural history of rapid disease progression. The risk calculus is completely different from an adult HAE patient who is currently managing fine on lanadelumab or berotralstat — annoying, yes, chronic injections or a daily pill — but not dying. The FDA will be asking a different question here.
Marcus Vale: That's actually the part I think people underestimate. Lanadelumab generates over six hundred million dollars a year in chronic prescriptions. Berotralstat is another line of recurring revenue. A one-time therapy that eliminates that spend — Intellia isn't just launching a drug, it's the commercial disruption that pharma runs war games against.
Ben Okonkwo: Hm. And that's exactly why payers will fight the price.
Marcus Vale: Why? The math closes. You pay once, you eliminate years of infusions and pills and hospital visits.
Ben Okonkwo: Curative therapies have historically faced the sharpest payer resistance, not the softest. Because the upfront number is large and the avoided cost is spread across a lifetime the payer may not cover. If a patient changes insurers in year four, the payer who paid for the one-time dose doesn't recoup the avoided chronic spend. That's not hypothetical — that's why outcomes-based contracts exist and why they're still incredibly hard to execute.
Marcus Vale: So — what's your actual concern? That lonvo-z fails to get approved, or that it gets approved and can't get paid for?
Ben Okonkwo: My concern is the rolling BLA targeting a first-half 2027 launch. That timeline is aggressive for a permanent genetic edit where the longest human follow-up is twenty-eight weeks. And Intellia is at a one-point-seven-three billion dollar market cap, burning cash — EPS was negative eighty-one cents in Q1 alone. They cannot self-fund a commercial launch at scale.
Marcus Vale: Right, so — that's the forced M&A window. The Phase 3 result doesn't de-risk Intellia. It creates a negotiating deadline. The BLA clock is running. Roche, Vertex — someone runs that acquisition math right now. And lonvo-z isn't the only asset on the table. nex-z, their parallel CRISPR program for hereditary ATTR, published Phase 1 results in the NEJM in 2025. Same platform, second indication validated. That is a platform acquisition, not a single-asset deal.
Ben Okonkwo: Now that I find genuinely interesting. Because Julian Gillmore's nex-z data does establish that the in vivo CRISPR liver-targeting mechanism is reproducible across diseases. That's not one lucky trial — that's platform evidence.
Marcus Vale: Exactly. Phase 1, Phase 2, Phase 3 for lonvo-z — all published in the New England Journal. Cohn, Longhurst, now the full HAELO results presented at EAACI in Istanbul. The publication record alone is a credibility signal that a large acquirer reads very differently than a press release.
Ben Okonkwo: But what experiment would have to fail for you to update the acquisition thesis? Because if a safety signal emerges in year three — unexpected coagulation findings from permanent kallikrein suppression, say — the acquiring company owns a permanent genetic edit with a live liability question. That's not an abstract risk. That's what makes in vivo CRISPR different from a small molecule or a biologic.
Marcus Vale: Frankly? If off-target editing produces an oncology signal in the long-term follow-up cohort. That would crater the platform, not just the asset.
Ben Okonkwo: And a fifty-two patient treated arm is too small to detect that. That's not a knock on Intellia — that's just how rare adverse events work statistically.
Marcus Vale: And that silence is its own answer, honestly. Like, if you're Intellia's comms team and you're not war-gaming the liability scenario out loud, you're basically pattern-matching to every other biotech that got caught flat-footed. The durability bet and the safety bet require opposite postures — different legal prep, different payer messaging, different everything.
Ben Okonkwo: Right. And those postures aren't even mutually exclusive to prepare for. What's strange is that they're not visibly preparing for either one. The question is whether that's a comms strategy or whether leadership genuinely believes the 24-week data is load-bearing enough that they don't think they need to.
Marcus Vale: Which would be the most expensive assumption in the history of in vivo CRISPR if they're wrong.
